EyePoint (EYPT) Change in Accured Expenses (2010 - 2026)
EyePoint (EYPT) posted Change in Accured Expenses of $571000.0 for Q1 2026, down 90.84% sequentially from $6.2 million in Q4 2025, and down 88.52% YoY from $5.0 million in Q1 2025.
Powered by 
Analysis
EyePoint (EYPT) Change in Accured Expenses (2010 - 2026) Analysis & Trends
EyePoint has reported Change in Accured Expenses for 17 years, with the latest figure at $571000.0 in Q1 2026.
- Quarterly Change in Accured Expenses fell 88.52% year-over-year to $571000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $274000.0 (down 97.74% YoY) and the FY2025 annual result came in at $4.7 million, down 18.39% from the prior year.
- Change in Accured Expenses fell to $571000.0 in Q1 2026 per EYPT's latest filing, from $6.2 million in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $8.1 million in Q4 2024 and troughed at -$6.0 million in Q3 2024.
- A 5-year average of $805647.1 and a median of $571000.0 in 2026 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses sank 263.13% in 2023, then soared 1017.17% in 2024.
- Over 5 years, Change in Accured Expenses stood at -$483000.0 in 2022, then soared by 250.72% to $728000.0 in 2023, then jumped by 1017.17% to $8.1 million in 2024, then dropped by 23.39% to $6.2 million in 2025, then plunged by 90.84% to $571000.0 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered $571000.0, $6.2 million, and -$3.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 11.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 55.78 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 212.44 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 61.62 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 68.82 Mn |
| 10 | EyePoint | 398.53 Mn | 218.06 Mn | 507,000.00 | 3.99 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.99 Mn |
| Mar 31, 2026 | 571,000.00 |
| Dec 31, 2025 | 6.23 Mn |
| Sep 30, 2025 | -3.06 Mn |
| Jun 30, 2025 | -3.47 Mn |
| Mar 31, 2025 | 4.97 Mn |
| Dec 31, 2024 | 8.13 Mn |
| Sep 30, 2024 | -6.04 Mn |
| Jun 30, 2024 | 5.07 Mn |
| Mar 31, 2024 | -1.43 Mn |
| Dec 31, 2023 | 728,000.00 |
| Sep 30, 2023 | -2.89 Mn |
| Jun 30, 2023 | 5.95 Mn |
| Mar 31, 2023 | -2.27 Mn |
| Dec 31, 2022 | -483,000.00 |
| Sep 30, 2022 | 1.77 Mn |
| Jun 30, 2022 | 2.02 Mn |
| Mar 31, 2022 | -2.11 Mn |
| Dec 31, 2021 | 3.45 Mn |
| Sep 30, 2021 | 3.68 Mn |